December 8, 2014 9:20 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
In a report published Monday, Citigroup analyst Garen Sarafian initiated coverage on
PRA Health Sciences (NASDAQ: PRAH) with a Neutral rating and $24.00 price target.In the report, Citigroup noted, “We are initiating on PRA Health Sciences with a Neutral rating and a $24 target price. PRAH, a Contract Research Organization (CRO), is performing well after its mid-2013 acquisition of peer ReSearch Pharmaceutical Services (RPS), allowing it to compete more closely with the world's largest and most diversified CROs. The acquisition also provided key exposure to top biopharmaceutical clients, complementary to legacy PRAs position with small/mid-sized biotechs. While we favor PRA's clinical focus & believe global CROs will benefit disproportionately from macro trends including our proprietary analysis of global drug trial starts, our relative view of valuations in the CRO subsector and PRA's ~20% price appreciation post-IPO keep us on the sidelines.”PRA Health Sciences closed on Friday at $22.06.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.